产品封面图

CRL-2016 SP2/MIL-6 小鼠骨髓瘤B淋巴细胞

收藏
  • 询价
  • ATCC
  • CRL-2016
  • 2025年12月05日
    avatar
    上海复祥生物科技有限公司
    14 年金牌会员

  • 企业认证

    点击 QQ 联系

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 供应商：

      复祥生物

    • 物种来源：

      小鼠

    • 生长状态：

      常温干冰

    • 库存：

      大量

    CRL-2016 SP2/MIL-6 小鼠骨髓瘤B淋巴细胞，ATCC 细胞|细胞系|细胞株|肿瘤细胞株|细胞|贴壁细胞|悬浮细胞|；细胞库管理规范，提供的细胞株背景清楚，提供参考文献和最优培养条件

    CRL-2016 SP2/MIL-6 小鼠骨髓瘤B淋巴细胞 的详细介绍
    CRL-2016 SP2/MIL-6 小鼠骨髓瘤B淋巴细胞
    ATCC® Number: CRL-2016™ Price: $399.00
    Designations: Sp2/mIL-6
    Depositors: JF Harris
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: suspension
    Organism: Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
    Morphology: lymphoblast
    Source: Cell Type: hybridoma: B lymphocyte;
    Cellular Products: mouse interleukin 6 (interleukin-6, IL-6)
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Restrictions: Note: These cells are distributed for research purposes only. Dr. Harris releases the line subject to the following: 1.) The Sp2/mIl-6 cells or any cells derived from SP2/mIL-6 or any antibody derived from it must not be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. 2.) Any proposed commercial use of these cells should first be negotiated with the London Regional Cancer Centre, 790 Commissioners Road, East, London, Ontario. N6A 4L6 Canada. 3.) In all papers reporting any use of these or derived clones a direct reference will be made to the original publication (J. Immunol. Methods 148: 199-207, 1992).
    Isolation: Toronto Ontario, Canada
    Antigen Expression: H-2, d haplotype; Mus musculus, expressed
    Comments: The Sp2/mIL-6 line was established by R. Hawley and T. Hawley of the Sunnybrook Health Centre, Toronto, Canada. It is a mouse fusion cell line derived from Sp2/0 cells that had been transfected with high-titer L6PNL recombinant retrovirus carrying a mouse interleukin-6 (IL-6) cDNA under the transcriptional control of the viral LTR and the neo gene encoding bacterial neomycin phosphotransferase (G418 resistance). Sp2/mIL-6 cells have stably incorporated in their genome approximately six copies of the retroviral vector L6PNL and constitutively secrete large quantities of mouse IL-6 (10,000 units/ml). Sp2/IL-6 cells secrete IL-6 and are an improved myeloma fusion parent in terms of both the relative number of viable B cell hybridomas producing immunoglobulin and the proportion of hybridomas producing antigen-specific monoclonal antibodies.
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water. To make the complete growth medium, add the following components to the base medium:
    • fetal bovine serum to a final concentration of 10%
      • 1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere
        • 0.05 mM 2-Mercaptoethanol

          • Temperature: 37.0°C
    Subculturing: Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start new cultures at 2 X 10(5) cells/ml and subculture before the cell density reaches 2 X 10(6) cells/ml.
    Medium Renewal: Add fresh medium every 2 to 4 days (depending on cell density)
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 46-X
    References: 23169: Harris JF, et al. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J. Immunol. Methods 148: 199-207, 1992. PubMed: 1373425

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验

    • 用于融合的动物骨髓细胞系

      率及所产生的杂交瘤细胞系的稳定性等方面均可与PS-X63-Ag8或P3-NS1/1-Ag4-1相比拟。 4．小鼠P3-X63-Ag8-U1（1980年Sharon）。是P3-X63-Ag8骨髓瘤细胞系的变系。P3-X63-Ag8分泌重链（rl）和轻链（K），P3-NS1/1-Ag4-1则只合成而不分泌轻链（K）。 5．小鼠SP2/O-Ag14（1978年Shulman）。Kohler等将PS-X63-Ag8骨髓瘤细胞系与具有抗绵羊红细胞活性、产生r2b重链和K轻链的BALB/c小鼠

    • 用于融合的动物骨髓细胞系

      率及所产生的杂交瘤细胞系的稳定性等方面均可与PS-X63-Ag8或P3-NS1/1-Ag4-1相比拟。 4．小鼠P3-X63-Ag8-U1（1980年Sharon）。是P3-X63-Ag8骨髓瘤细胞系的变系。P3-X63-Ag8分泌重链（rl）和轻链（K），P3-NS1/1-Ag4-1则只合成而不分泌轻链（K）。 5．小鼠SP2/O-Ag14（1978年Shulman）。Kohler等将PS-X63-Ag8骨髓瘤细胞系与具有抗绵羊红细胞活性、产生r2b重链和K轻链的BALB/c小鼠

    • 制备单克隆抗体骨髓瘤细胞的选择

      DNA，因而对HAT敏感。 目前常用的小鼠骨髓瘤细胞系为SP2 /O和NS-1 ，X63Ag8.653等。均来自BALB/c小鼠骨髓瘤。刚复苏的瘤细胞需在含10％新鲜小牛血清的RPMI-1640培养液中，5％CO2 37℃ 孵箱培养。每2～3天换液一次，3～5天传代一次，待细胞生长稳定后方可供细胞融合用。生长良好的细胞，在倒置显微镜下观察为圆形明亮，排列整齐、形态完整，密度适宜(0.1～1×106 个/ml)。经台盼蓝染色，活细胞数应>90％。实验室培养的骨髓瘤细胞最好每隔3～6个月将细胞

    查看更多相关实验 >
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    SP2/MIL-6细胞,小鼠骨髓瘤B淋巴细胞；SP2/MIL-6,SP2/MIL-6细胞小鼠骨髓瘤B淋巴细胞；SP2/MIL-6
    询价
    蒂科（上海）生物科技有限公司
    2025年12月09日询价
    SP2/MIL-6小鼠骨髓瘤B淋巴细胞
    ￥2800
    上海雅吉生物科技有限公司
    2025年07月15日询价
    SP2/MIL-6小鼠骨髓瘤B淋巴细胞
    ￥500
    上海酶研生物科技有限公司
    2025年12月31日询价
    小鼠骨髓瘤B淋巴细胞；SP2/MIL-6
    ￥900
    上海淳麦生物科技有限公司
    2025年07月15日询价
    小鼠骨髓瘤B淋巴细胞；SP2/MIL-6
    ￥1800
    上海博尔森生物科技有限公司
    2025年12月30日询价
    CRL-2016 SP2/MIL-6 小鼠骨髓瘤B淋巴细胞
    询价